Table 1. Baseline clinicopathological characteristics.
| Characteristic | SEER (N=69,178) (%) | FUSCC (N=3,137) (%) | |||||
|---|---|---|---|---|---|---|---|
| TD-positive (n=8,480) | TD-negative (n=60,698) | P | TD-positive (n=463) | TD-negative (n=2,674) | P | ||
| Age, years | <0.001 | 0.874 | |||||
| <65 | 3,835 (13.8) | 23,860 (86.2) | 142 (14.6) | 830 (85.4) | |||
| ≥65 | 4,645 (11.2) | 36,838 (88.8) | 321 (14.8) | 1,844 (85.2) | |||
| Sex | 0.288 | 0.975 | |||||
| Male | 4,246 (12.4) | 30,018 (87.6) | 269 (14.7) | 1,564 (85.3) | |||
| Female | 4,234 (12.1) | 30,680 (87.9) | 194 (14.9) | 1,110 (85.1) | |||
| Location | <0.001 | 0.032 | |||||
| Colon | 4,999 (11.9) | 39,091 (88.1) | 198 (13.3) | 1,290 (86.7) | |||
| Rectum | 3,298 (13.9) | 20,660 (86.1) | 264 (16.2) | 1,364 (83.8) | |||
| Unknown | 183 (16.2) | 947 (83.8) | 1 (4.8) | 20 (95.2) | |||
| pT stage | <0.001 | <0.001 | |||||
| T0/Tis | 7 (0.7) | 1,008 (99.3) | – | – | |||
| T1/T2 | 370 (2.0) | 18,190 (98.0) | 62 (8.2) | 694 (91.8) | |||
| T3/T4 | 8,094 (16.4) | 41,386 (83.6) | 399 (17.2) | 1,917 (82.8) | |||
| Unknown | 9 (7.8) | 106 (92.2) | 2 (3.1) | 63 (96.9) | |||
| pN stage | <0.001 | <0.001 | |||||
| N0 | 1,715 (4.2) | 38,828 (95.8) | 96 (5.7) | 1,600 (94.3) | |||
| N1 | 2,503 (15.6) | 13,535 (84.4) | 155 (19.3) | 649 (80.7) | |||
| N2 | 4,262 (33.8) | 8,335 (66.2) | 212 (33.3) | 425 (66.7) | |||
| Venous invasion | – | <0.001 | |||||
| Positive | – | – | 193 (24.9) | 581 (75.1) | |||
| Negative | – | – | 253 (11.1) | 2,026 (88.9) | |||
| Unknown | – | – | 17 (20.2) | 67 (79.8) | |||
| Perineural invasion | <0.001 | <0.001 | |||||
| Positive | 2,165 (35.2) | 4,806 (64.8) | 202 (30.3) | 464 (69.7) | |||
| Negative | 5,131 (9.2) | 50,810 (90.8) | 260 (10.8) | 2,151 (89.2) | |||
| Unknown | 734 (12.6) | 5,082 (87.4) | 1 (1.7) | 59 (98.3) | |||
SEER, Surveillance Epidemiology and End Results; FUSCC, Fudan University Shanghai Cancer Center; TD, tumor deposit.